In July of 2020, bulevirtide was conditionally approved for the treatment of adults with compensated chronic hepatitis D. Some clinical studies have evaluated the safety and efficacy of bulevirtide as a treatment option for chronic hepatitis D in recent years. Herein are presented a brief review and an outline.
2020年7月，bulevirtide获批用于成人代偿期慢性丁型肝炎的治疗；近年来，多项研究评估了bulevirtide用于治疗慢性丁型肝炎的安全性和有效性，现对此进行简要综述并提出目前面临的挑战。.